Raymond James & Associates’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | $189M | Sell |
1,214,635
-73,733
| -6% | -$11.9M | 0.12% | 160 |
|
|
2024
Q2 | $201M | Sell |
1,288,368
-3,902
| -0.3% | -$587K | 0.13% | 130 |
|
|
2024
Q1 | $175M | Buy |
1,292,270
+86,524
| +7% | +$11.5M | 0.12% | 158 |
|
|
2023
Q4 | $162M | Buy |
1,205,746
+4,027
| +0.3% | +$524K | 0.12% | 151 |
|
|
2023
Q3 | $163M | Sell |
1,201,719
-112,444
| -9% | -$15.4M | 0.14% | 137 |
|
|
2023
Q2 | $188M | Buy |
1,314,163
+25,628
| +2% | +$3.77M | 0.15% | 117 |
|
|
2023
Q1 | $179M | Buy |
1,288,535
+88,336
| +7% | +$11.9M | 0.16% | 120 |
|
|
2022
Q4 | $163M | Sell |
1,200,199
-69,366
| -5% | -$8.7M | 0.15% | 133 |
|
|
2022
Q3 | $139M | Buy |
1,269,565
+39,549
| +3% | +$5.02M | 0.14% | 135 |
|
|
2022
Q2 | $163M | Buy |
1,230,016
+58,585
| +5% | +$7.69M | 0.16% | 117 |
|
|
2022
Q1 | $155M | Buy |
1,171,431
+102,988
| +10% | +$12.4M | 0.13% | 145 |
|
|
2021
Q4 | $124M | Sell |
1,068,443
-18,333
| -2% | -$2.16M | 0.1% | 183 |
|
|
2021
Q3 | $131M | Buy |
1,086,776
+345,247
| +47% | +$40.2M | 0.12% | 161 |
|
|
2021
Q2 | $88.8M | Buy |
741,529
+55,981
| +8% | +$6.14M | 0.08% | 209 |
|
|
2021
Q1 | $68.2M | Buy |
685,548
+125,386
| +22% | +$12.6M | 0.07% | 239 |
|
|
2020
Q4 | $56M | Sell |
560,162
-72,012
| -11% | -$7.63M | 0.06% | 261 |
|
|
2020
Q3 | $69.3M | Sell |
632,174
-47,919
| -7% | -$5.33M | 0.09% | 190 |
|
|
2020
Q2 | $71.9M | Buy |
680,093
+42,811
| +7% | +$4.42M | 0.1% | 178 |
|
|
2020
Q1 | $56.9M | Buy |
637,282
+32,505
| +5% | +$3.06M | 0.09% | 190 |
|
|
2019
Q4 | $60.3M | Buy |
604,777
+3,529
| +0.6% | +$332K | 0.08% | 230 |
|
|
2019
Q3 | $53.6M | Sell |
601,248
-36,822
| -6% | -$3.19M | 0.07% | 241 |
|
|
2019
Q2 | $52.7M | Sell |
638,070
-82,667
| -11% | -$6.48M | 0.08% | 245 |
|
|
2019
Q1 | $58.3M | Sell |
720,737
-590,027
| -45% | -$46.5M | 0.09% | 217 |
|
|
2018
Q4 | $99.6M | Sell |
1,310,764
-169,232
| -11% | -$13.2M | 0.17% | 107 |
|
|
2018
Q3 | $117M | Sell |
1,479,996
-295,323
| -17% | -$22.3M | 0.18% | 104 |
|
|
2018
Q2 | $125M | Sell |
1,775,319
-163,298
| -8% | -$11.7M | 0.21% | 89 |
|
|
2018
Q1 | $136M | Sell |
1,938,617
-206,564
| -10% | -$14.3M | 0.24% | 84 |
|
|
2017
Q4 | $149M | Buy |
2,145,181
+87,015
| +4% | +$5.87M | 0.27% | 71 |
|
|
2017
Q3 | $139M | Buy |
2,058,166
+231,269
| +13% | +$14.6M | 0.28% | 68 |
|
|
2017
Q2 | $125M | Buy |
1,826,897
+41,167
| +2% | +$2.69M | 0.27% | 71 |
|
|
2017
Q1 | $111M | Buy |
1,785,730
+565,545
| +46% | +$32.9M | 0.26% | 81 |
|
|
2016
Q4 | $66.7M | Sell |
1,220,185
-114,374
| -9% | -$6.49M | 0.17% | 122 |
|
|
2016
Q3 | $87.7M | Buy |
1,334,559
+703,651
| +112% | +$46M | 0.24% | 88 |
|
|
2016
Q2 | $38.1M | Buy |
630,908
+52,318
| +9% | +$3.04M | 0.12% | 186 |
|
|
2016
Q1 | $32.6M | Buy |
578,590
+20,392
| +4% | +$1.23M | 0.11% | 198 |
|
|
2015
Q4 | $37.9M | Buy |
558,198
+19,365
| +4% | +$1.27M | 0.14% | 158 |
|
|
2015
Q3 | $34.3M | Buy |
538,833
+106,535
| +25% | +$7.01M | 0.14% | 157 |
|
|
2015
Q2 | $27.5M | Buy |
432,298
+43,413
| +11% | +$2.97M | 0.11% | 210 |
|
|
2015
Q1 | $26.6M | Buy |
388,885
+160,739
| +70% | +$11.2M | 0.12% | 190 |
|
|
2014
Q4 | $16.1M | Buy |
228,146
+13,289
| +6% | +$952K | 0.08% | 275 |
|
|
2014
Q3 | $15.3M | Buy |
214,857
+15,776
| +8% | +$1.15M | 0.09% | 245 |
|
|
2014
Q2 | $14.8M | Sell |
199,081
-534,036
| -73% | -$38.6M | 0.09% | 233 |
|
|
2014
Q1 | $47.6M | Sell |
733,117
-37,730
| -5% | -$2.44M | 0.33% | 46 |
|
|
2013
Q4 | $45.8M | Sell |
770,847
-8,643
| -1% | -$470K | 0.34% | 48 |
|
|
2013
Q3 | $40.5M | Buy |
779,490
+88,656
| +13% | +$4.45M | 0.35% | 47 |
|
|
2013
Q2 | $32.7M | Buy |
+690,834
| New | +$35.2M | 0.31% | 60 |
|
Other funds holding AZN
Raymond James & Associates's AZN Position: Q3 2024 in Review
Raymond James & Associates reduced its AstraZeneca (AZN) stake by 5.7% in Q3 2024, selling an estimated $11.9M and leaving 1,214,635 shares worth $189M. The position accounts for 0.12% of the portfolio, ranked #160.
Raymond James & Associates first reported a position in AZN in Q2 2013 and has held it in 46 quarters since. The position peaked at $201M in Q2 2024. 1,229 funds tracked by Wall St. Rank hold AZN as of Q3 2024.
- Raymond James & Associates held 1,214,635 shares of AstraZeneca worth $189M as of Q3 2024.
- Raymond James & Associates sold 73,733 AstraZeneca shares in Q3 2024, an estimated $11.9M.
- AstraZeneca made up 0.12% of Raymond James & Associates's portfolio in Q3 2024, its #160 holding.
- Raymond James & Associates first reported a position in AstraZeneca in Q2 2013 and has held it in 46 quarters since.
- Raymond James & Associates's AstraZeneca position peaked at $201M in Q2 2024.
- 1,229 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2024.
Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.